Advanced

Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis.

Hedner, Ulla LU and Ezban, Mirella (2008) In Annual Review of Medicine 59. p.29-41
Abstract
For hemophilia patients with inhibitors against FVIII or FIX, the development of recombinant factor VIIa (rFVIIa) raises the possibility of a therapeutic alternative whose availability and convenience of treatment are comparable to those of FVIII or FIX. In support of this new concept for the treatment of bleeding episodes, pharmacological doses of FVIIa have been shown to induce hemostasis. Pharmacological doses of rFVIIa enhance thrombin generation on thrombin-activated platelets, thereby facilitating the formation of strong, well-structured fibrin plugs resistant to premature proteolysis. Modified rFVIIa molecules with a stronger hemostatic potential have been produced. Inhibition of the FVII-TF-dependent pathway (TFPI and rFVIIai) has... (More)
For hemophilia patients with inhibitors against FVIII or FIX, the development of recombinant factor VIIa (rFVIIa) raises the possibility of a therapeutic alternative whose availability and convenience of treatment are comparable to those of FVIII or FIX. In support of this new concept for the treatment of bleeding episodes, pharmacological doses of FVIIa have been shown to induce hemostasis. Pharmacological doses of rFVIIa enhance thrombin generation on thrombin-activated platelets, thereby facilitating the formation of strong, well-structured fibrin plugs resistant to premature proteolysis. Modified rFVIIa molecules with a stronger hemostatic potential have been produced. Inhibition of the FVII-TF-dependent pathway (TFPI and rFVIIai) has been tried in attempts to prevent thrombosis, with promising results in animal models so far not confirmed in clinical trials. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annual Review of Medicine
volume
59
pages
29 - 41
publisher
Annual Reviews
external identifiers
  • wos:000253397600003
  • scopus:39649106357
ISSN
0066-4219
DOI
10.1146/annurev.med.59.061606.095605
language
English
LU publication?
yes
id
ed1226ec-b302-4de5-bc2c-37b2e5781b43 (old id 607901)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17845136&dopt=Abstract
date added to LUP
2009-07-27 16:53:52
date last changed
2017-11-19 03:33:44
@article{ed1226ec-b302-4de5-bc2c-37b2e5781b43,
  abstract     = {For hemophilia patients with inhibitors against FVIII or FIX, the development of recombinant factor VIIa (rFVIIa) raises the possibility of a therapeutic alternative whose availability and convenience of treatment are comparable to those of FVIII or FIX. In support of this new concept for the treatment of bleeding episodes, pharmacological doses of FVIIa have been shown to induce hemostasis. Pharmacological doses of rFVIIa enhance thrombin generation on thrombin-activated platelets, thereby facilitating the formation of strong, well-structured fibrin plugs resistant to premature proteolysis. Modified rFVIIa molecules with a stronger hemostatic potential have been produced. Inhibition of the FVII-TF-dependent pathway (TFPI and rFVIIai) has been tried in attempts to prevent thrombosis, with promising results in animal models so far not confirmed in clinical trials.},
  author       = {Hedner, Ulla and Ezban, Mirella},
  issn         = {0066-4219},
  language     = {eng},
  pages        = {29--41},
  publisher    = {Annual Reviews},
  series       = {Annual Review of Medicine},
  title        = {Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis.},
  url          = {http://dx.doi.org/10.1146/annurev.med.59.061606.095605},
  volume       = {59},
  year         = {2008},
}